BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 1776864)

  • 1. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G; Zeller WJ
    Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
    Xu BH; Singh SV
    Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA; Greene K; Ahmad S; Vistica DT
    Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin.
    Chen G; Zeller WJ
    Anticancer Res; 1993; 13(1):219-23. PubMed ID: 8476216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL; Hwang J; Perng RP; Whang-Peng J
    Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K; Shrieve DC
    J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.
    Frühauf S; Zeller WJ
    Cancer Res; 1991 Jun; 51(11):2943-8. PubMed ID: 2032232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
    Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
    Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
    Chen G; Zeller WJ; Todorov DK
    Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
    Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE; Hahn SM; Cook JA; Lipschultz C; Mitchell JB; Kaufman DC
    Cancer Res; 1993 May; 53(9):2066-70. PubMed ID: 8097674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion.
    Andrews PA; Murphy MP; Howell SB
    Cancer Res; 1985 Dec; 45(12 Pt 1):6250-3. PubMed ID: 4063975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines.
    Peters RH; Jollow DJ; Stuart RK
    Cancer Res; 1991 May; 51(10):2536-41. PubMed ID: 2021933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
    Soble MJ; Dorr RT
    Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Shellard SA; Hosking LK; Hill BT
    Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
    Hansson J; Edgren M; Ehrsson H; Ringborg U; Nilsson B
    Cancer Res; 1988 Jan; 48(1):19-26. PubMed ID: 3334994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
    Xu BH; Gupta V; Singh SV
    Arch Biochem Biophys; 1994 Jan; 308(1):164-70. PubMed ID: 8311448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery.
    Bertsche U; Schorn H
    Radiat Res; 1986 Mar; 105(3):351-69. PubMed ID: 3754339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P; Loh SY; Kelland LR; Harrap KR
    Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.